
ADMA
ADMA Biologics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
18.410
Open
17.360
VWAP
18.10
Vol
3.28M
Mkt Cap
4.30B
Low
17.335
Amount
59.33M
EV/EBITDA(TTM)
26.89
Total Shares
231.81M
EV
4.30B
EV/OCF(TTM)
42.49
P/S(TTM)
9.60
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
139.85M
+18.97%
--
--
128.80M
+7.48%
--
--
122.05M
+13.86%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for ADMA Biologics, Inc. (ADMA) for FY2025, with the revenue forecasts being adjusted by 3.78% over the past three months. During the same period, the stock price has changed by -26.52%.
Revenue Estimates for FY2025
Revise Upward

+3.78%
In Past 3 Month
Stock Price
Go Down

-26.52%
In Past 3 Month
3 Analyst Rating

70.29% Upside
Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 30.67 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

70.29% Upside
Current: 18.010

Low
25.00
Averages
30.67
High
35.00

70.29% Upside
Current: 18.010

Low
25.00
Averages
30.67
High
35.00
Raymond James
Strong Buy
maintain
$25 -> $32
2025-05-08
Reason
Raymond James
Price Target
$25 -> $32
2025-05-08
maintain
Strong Buy
Reason
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$25
2025-03-04
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$25
2025-03-04
Reiterates
Buy
Reason
Raymond James
Elliot Wilbur
Strong Buy
Maintains
$18 → $25
2024-11-08
Reason
Raymond James
Elliot Wilbur
Price Target
$18 → $25
2024-11-08
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$18 → $26
2024-11-08
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18 → $26
2024-11-08
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$18
2024-10-14
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18
2024-10-14
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$20
2024-09-20
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$20
2024-09-20
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for ADMA Biologics Inc (ADMA.O) is 25.25, compared to its 5-year average forward P/E of -1.42. For a more detailed relative valuation and DCF analysis to assess ADMA Biologics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.42
Current PE
25.25
Overvalued PE
50.10
Undervalued PE
-52.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
9.30
Current EV/EBITDA
15.65
Overvalued EV/EBITDA
19.08
Undervalued EV/EBITDA
-0.49
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued
5Y Average PS
4.23
Current PS
7.67
Overvalued PS
6.76
Undervalued PS
1.69
Financials
Annual
Quarterly
FY2025Q1
YoY :
+40.22%
114.80M
Total Revenue
FY2025Q1
YoY :
+59.85%
34.88M
Operating Profit
FY2025Q1
YoY :
+51.10%
26.90M
Net Income after Tax
FY2025Q1
YoY :
+37.50%
0.11
EPS - Diluted
FY2025Q1
YoY :
+432.64%
-24.40M
Free Cash Flow
FY2025Q1
YoY :
+11.93%
53.20
Gross Profit Margin - %
FY2025Q1
YoY :
+249.64%
19.65
FCF Margin - %
FY2025Q1
YoY :
+7.77%
23.44
Net Margin - %
FY2025Q1
62.04
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
10.9M
USD
10
3-6
Months
848.0K
USD
2
6-9
Months
1.4M
USD
2
0-12
Months
15.0M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 719.51% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
169.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
2.1M
Volume
Months
6-9
1
254.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
10.9M
USD
10
3-6
Months
848.0K
USD
2
6-9
Months
1.4M
USD
2
0-12
Months
15.0M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ADMA News & Events
Events Timeline
2025-04-28 (ET)
2025-04-28
07:09:36
Adma announces U.S. FDA approval of production yield enhancement process

2025-04-07 (ET)
2025-04-07
07:07:34
ADMA Biologics reiterates 'strategic advantage' through U.S.-based manufacturing

2025-03-03 (ET)
2025-03-03
16:59:23
Adma Biologics sees FY26 revenue at least $605M

Sign Up For More Events
Sign Up For More Events
News
2.0
07-16NASDAQ.COMAdma Biologics (ADMA) Declines More Than Market: Some Information for Investors
2.0
06-27NASDAQ.COMAdma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
2.0
06-25NASDAQ.COMADMA Biologics Becomes Oversold
Sign Up For More News
People Also Watch

MHO
M/I Homes Inc
122.190
USD
+0.90%

PI
Impinj Inc
124.250
USD
+2.86%

CPA
Copa Holdings SA
110.120
USD
-0.16%

XRAY
DENTSPLY SIRONA Inc
16.030
USD
-2.61%

BL
BlackLine Inc
56.000
USD
-0.90%

EBC
Eastern Bankshares Inc
15.960
USD
+1.20%

TCBI
Texas Capital Bancshares Inc
85.300
USD
-1.31%

MDU
MDU Resources Group Inc
17.020
USD
+0.95%

PJT
PJT Partners Inc
184.100
USD
-1.03%

RUSHA
Rush Enterprises Inc
54.820
USD
+1.05%
FAQ

What is ADMA Biologics Inc (ADMA) stock price today?
The current price of ADMA is 18.01 USD — it has increased 4.04 % in the last trading day.

What is ADMA Biologics Inc (ADMA)'s business?

What is the price predicton of ADMA Stock?

What is ADMA Biologics Inc (ADMA)'s revenue for the last quarter?

What is ADMA Biologics Inc (ADMA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ADMA Biologics Inc (ADMA)'s fundamentals?

How many employees does ADMA Biologics Inc (ADMA). have?
